The Icahn School of Medicine at Mount Sinai proposes to continue a highly successful Training Program in Cancer Biology for predoctoral students and postdoctoral fellows. Its leadership has extensive experience in cancer research mentoring and a well-documented commitment to both graduate education and postrdoctoral training. This institutional program encompasses training faculty from 6 basic and 4 clinical departments as well as 12 matrix institutes and involves laboratory and computational research. The dynamic and interdisciplinary nature of the Program is evidenced by co- authored papers and and multi-investigator grants, as well as the 34% increase in training faculty since the initia application in 2013. All faculty members have peer-reviewed R01 or R01-equivalent support from funding agencies for cancer-related studies. The Program attracts and develops a cadre of outstanding Ph.D. and M.D., Ph.D. students, and postdoctoral fellows, with our earliest trainees having established cancer-focused research careers at prestigious institutions. The curriculum for predoctoral and postdoctoral trainees involves common elements including a new advanced didactic cancer biology course and advanced electives, which impart state-of-the-art training in emerging technologies critical to basic and translational cancer investigations. All trainees also participate in regular conferences, which further expose them to clinical aspects of cancer. There are important specific training elements for each component as well. There is a rigorous evaluation and selection process, and the program is both cognizant of and actively involved in diversity recruitment. New components of the program also include additional training venues to specifically aid postdoctoral trainees in seeking academic positions and a formal training faculty track in which promising junior faculty members may apply with a training faculty member to co-mentor a highly qualified trainee, an approach providing mentorship by the training faculty member both of the trainee and the faculty co-mentor. The program has contributed importantly to the remarkable increase in cancer research and NCI funding over the past decade. Mount Sinai has also made enormous commitments in resources and facilities benefitting the Program including support for specific elements by the Tisch Cancer Institute and the Department of Oncological Sciences. Trainees work closely with faculty drawn from throughout Mount Sinai ensuring that their training is both rigorous and sufficiently broad in scope to take into account practical issues faced by physicians in preventing and treating cancer.

Public Health Relevance

Cancer biology research within this institutional, multidisciplinary training program is aimed at elucidating the molecular mechanisms responsible for initiation and progression of human cancer. Translational research is also directed at improving diagnosis and therapies for this terrible disease, and our training faculty have made discoveries that have led to new cancer therapies. Both pre- and postdoctoral trainees participate in rigorous didactic as well as state-of-the-art laboratory and/or computational research training with the earliest cadre having now established academic careers in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA078207-16A1
Application #
8855124
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1999-07-20
Project End
2020-08-31
Budget Start
2015-09-23
Budget End
2016-08-31
Support Year
16
Fiscal Year
2015
Total Cost
$464,142
Indirect Cost
$31,844
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
D'Avola, Delia; Villacorta-Martin, Carlos; Martins-Filho, Sebastiao N et al. (2018) High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Sci Rep 8:11570
Sonoshita, Masahiro; Scopton, Alex P; Ung, Peter M U et al. (2018) A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol 14:291-298
Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia et al. (2018) A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 37:3740-3752
Bane, Octavia; Hectors, Stefanie J; Wagner, Mathilde et al. (2018) Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med 79:2564-2575
Craig, Amanda J; von Felden, Johann; Villanueva, Augusto (2017) Molecular profiling of liver cancer heterogeneity. Discov Med 24:117-125
Lin, Su-Jiun; O'Connell, Matthew J (2017) DNA Topoisomerase II modulates acetyl-regulation of cohesin-mediated chromosome dynamics. Curr Genet 63:923-930
Kenny, Timothy C; Manfredi, Giovanni; Germain, Doris (2017) The Mitochondrial Unfolded Protein Response as a Non-Oncogene Addiction to Support Adaptation to Stress during Transformation in Cancer and Beyond. Front Oncol 7:159
Kalan, Sampada; Amat, Ramon; Schachter, Miriam Merzel et al. (2017) Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep 21:467-481
Pappas, Kyrie; Xu, Jia; Zairis, Sakellarios et al. (2017) p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. Mol Cancer Res 15:1051-1062
Senturk, J C; Bohlman, S; Manfredi, J J (2017) Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53. Oncogene 36:6085-6096

Showing the most recent 10 out of 96 publications